Key Takeaways
- UnitedHealth delivered Q2 adjusted earnings of $6.38 per share, significantly exceeding the Street’s $4.91 projection
- Quarterly revenue reached $112 billion, surpassing analyst expectations of $110.8 billion
- The medical-cost ratio improved to 86.7%, a notable decline from last year’s 89.4%
- Management elevated full-year adjusted EPS outlook to $19.50–$20.00 range, up from prior guidance floor of $18.25
- Baird analyst upgraded the stock to Hold from Sell, increasing price target from $287 to $453
Shares of UnitedHealth (UNH) jumped approximately 8% during Thursday’s trading session following the health insurance giant’s impressive second-quarter performance. The company reported adjusted earnings of $6.38 per share, handily beating the analyst consensus of $4.91. Top-line results also impressed, with revenue reaching $112 billion against forecasts of $110.8 billion.
UnitedHealth Group Incorporated, UNH
Prior to the earnings announcement, the stock had already gained roughly 27% since the beginning of the year. The quarterly figures delivered what the market was seeking: consecutive quarters demonstrating effective management of medical expenses.
The critical metric under scrutiny was the medical-cost ratio, which registered at 86.7% — representing a decrease from 89.4% recorded in the same period last year and outperforming the 88.4% Wall Street projection. When this ratio declines, it indicates the insurer retains a larger portion of premium revenue.
Company leadership attributed the favorable trend to “product design changes, improved medical management, and better aligned pricing” initiatives.
The healthcare giant also increased its full-year adjusted earnings per share forecast to a band of $19.50 to $20.00, representing an upward revision from the earlier bottom threshold of $18.25. Analyst consensus had previously settled at $18.49.
Broader Health Insurance Sector Gains Momentum
The positive momentum extended beyond UNH alone. Shares of Humana (HUM) and CVS Health — parent company of insurer Aetna — both advanced approximately 1% following market open. These three companies all have significant stakes in the Medicare Advantage sector, which has faced challenges from rising medical costs.
UnitedHealth has been strategically reducing its Medicare Advantage footprint to safeguard profit margins. The organization now anticipates full-year Medicare Advantage enrollment to decrease by approximately 1.1 million members.
During the earnings conference call, Tim Noel, CEO of UnitedHealthcare, noted that Medicare cost trends are “still running well above historical levels, but below our expectations so far in 2026.” He attributed the improvement to benefit restructuring and enhanced care management approaches.
Raymond James analyst John Ransom characterized the results as “a strong 2Q” that was “widely expected” and suggested it “should be good enough to keep the rally going.”
Wells Fargo’s Stephen Baxter commented that “UNH’s momentum exiting 2Q26 appears quite strong.”
Analyst Upgrade Accompanied by Cautious Outlook on Certain Segments
On Friday, UNH extended its gains by an additional 3% following a rating upgrade from Baird analyst Michael Ha, who moved the stock from Sell to Hold while raising his price objective to $453 from $287. Ha pointed to increasing confidence in near-term Medicare Advantage margin expansion and moderating healthcare cost inflation.
His examination of sector-wide data indicates Medicare Advantage utilization has moderated during the current year, with evidence of “flatter provider coding intensity growth.” Should this trend persist, it could support MA margin improvement through 2027.
Despite the upgrade, Ha expressed reservations regarding Optum Health’s capacity to achieve its long-range margin objective of 6%–8%, particularly considering potential challenges from anticipated MA risk model adjustments slated for early 2027.
He also highlighted concerns within Optum Insight, citing margin fluctuations, limited backlog transparency, and uncertainty surrounding client retention rates.
The overall Wall Street sentiment on UNH stands at a Strong Buy consensus, supported by 19 Buy recommendations and four Hold ratings. The mean price target of $450.91 suggests approximately 4% potential upside from present trading levels.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
